IP Verse

Astellas competitive analysis

Latest publications and patents of Astellas New

Explore the latest publications and patents granted to Astellas, showcasing their recent innovations and technological advancements.

Last updated on: Sep 24, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Astellas

EP3791896
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerGranted And Under Opposition
EP3318259
Jan 11, 2023Stable Pharmaceutical Composition For Oral AdministrationGranted And Under Opposition
EP2780022
Sep 7, 2022Pharmaceutical Preparations Of Human Rpe Cells And Uses ThereofPatent Maintained As Amended
EP3725810
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerRevoked
EP3725778
Aug 18, 2021Formulations Of EnzalutamideGranted And Under Opposition
EP2345410
Dec 30, 2020Controlled Release Pharmaceutical CompositionGranted And Under Opposition
EP3254695
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerGranted And Under Opposition
EP2824181
Nov 14, 2018Novel Fgfr3 Fusion ProductRevoked
EP2554168
Jan 24, 2018Controlled Release Pharmaceutical CompositionRevoked
EP2125897
Jan 17, 2018Monoclonal Antibodies For Treatment Of CancerNo Opposition Filed Within Time Limit

Latest patents of Astellas opposed by its competitors

Explore Astellas's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3791896
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
EP3318259
Jan 11, 2023Stable Pharmaceutical Composition For Oral Administration2
EP2780022
Sep 7, 2022Pharmaceutical Preparations Of Human Rpe Cells And Uses Thereof1
EP3725810
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2
EP3725778
Aug 18, 2021Formulations Of Enzalutamide11
EP2345410
Dec 30, 2020Controlled Release Pharmaceutical Composition6
EP3254695
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1
EP2824181
Nov 14, 2018Novel Fgfr3 Fusion Product2
EP2554168
Jan 24, 2018Controlled Release Pharmaceutical Composition4

Latest PTAB cases involving Astellas

Discover the latest PTAB cases involving Astellas, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 30, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Astellas

IPR2020-00764Mar 31, 2020ASTELLASIMPERIAL COLLEGE INNOVATIONSFinal Written Decision
IPR2018-00079Oct 16, 2017SAWAI PHARMACEUTICALASTELLAS PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Astellas with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
ASTELLAS PHARMA - 31 - 1Non-Active
BULLE DR19 - - - Highly Aggressive
MAIWALD132 - - - Highly Aggressive
SANDOZ1141519 - Highly Aggressive